Identification

Name
Oxacillin
Accession Number
DB00713  (APRD01149)
Type
Small Molecule
Groups
Approved
Description

An antibiotic similar to flucloxacillin used in resistant staphylococci infections. [PubChem]

Structure
Thumb
Synonyms
  • (2S,5R,6R)-3,3-Dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
  • (5-Methyl-3-phenyl-4-isoxazolyl)penicillin
  • 5-Methyl-3-phenyl-4-isoxazolyl-penicillin
  • 6beta-(5-Methyl-3-phenylisoxazol-4-yl)penicillanic acid
  • Oxacilina
  • Oxacillin
  • Oxacilline
  • Oxacillinum
  • Oxazocillin
  • Oxazocilline
External IDs
AB 1400 / BRL 1400 / P 12 / SQ 16423
Product Ingredients
IngredientUNIICASInChI Key
Oxacillin Sodium4TWD2995UP1173-88-2VDUVBBMAXXHEQP-UHFFFAOYSA-M
Oxacillin Sodium MonohydrateG0V6C994Q57240-38-2Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxacillinInjection, solution1 g/50mLIntravenousBaxter Laboratories1989-10-26Not applicableUs
OxacillinInjection, solution2 g/50mLIntravenousBaxter Laboratories1989-10-26Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxacillinInjection, powder, for solution1 g/1Intramuscular; IntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-08-262017-09-29Us
OxacillinInjection, powder, for solution1 g/1IntravenousSandoz1986-12-23Not applicableUs
OxacillinPowder, for solution1 g/1Intramuscular; IntravenousHospira, Inc.2015-12-112017-01-10Us
OxacillinInjection, powder, for solution1 g/1Intramuscular; IntravenousTeva Parenteral Medicines, Inc.2014-08-262017-09-30Us
OxacillinInjection, powder, for solution2 g/1Intramuscular; IntravenousSagent Pharmaceuticals2012-06-01Not applicableUs
OxacillinInjection, powder, for solution2 g/1IntravenousSandoz1986-12-23Not applicableUs
OxacillinInjection, powder, for solution2 g/2gIntramuscular; IntravenousRenaissance Ssa, Llc2017-09-11Not applicableUs
OxacillinInjection, powder, for solution10 g/100mLIntravenousSandoz1991-05-09Not applicableUs
OxacillinInjection, powder, for solution2 g/1Intramuscular; IntravenousAuro Medics Pharma Llc2013-01-18Not applicableUs
OxacillinInjection, powder, for solution10 g/100mLIntravenousSandoz1991-05-09Not applicableUs
International/Other Brands
Bactocill (Baxter Healthcare) / Biocilina (Biogalenic) / Bristopen (Bristol-Myers Squibb) / Dicloxal Ox (Magma) / InfectoStaph (Infectopharm) / Ocillina (CCPC) / Oxacil (Unimed) / Oxacilina (Billi Farmacêutica) / Oxacilinã (Antibiotice) / Oxagram (Medicef) / Oxal (Endure Medical) / Oxamicin (Ronava) / Oxapen (Biolab) / Oxipen (Behrens) / Panadox (Shijiazhuang) / Penstapho (Bristol-Myers Squibb) / Prostafilina (Bristol-Myers Squibb) / Prostaphlin (Bristol-Myers Squibb) / Stafcil (Aurobindo) / Staficilin-N (Bristol-Myers Squibb) / Wydox (YSS)
Categories
UNII
UH95VD7V76
CAS number
66-79-5
Weight
Average: 401.436
Monoisotopic: 401.104541423
Chemical Formula
C19H19N3O5S
InChI Key
UWYHMGVUTGAWSP-JKIFEVAISA-N
InChI
InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
IUPAC Name
(2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-phenyl-1,2-oxazole-4-amido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
[H][[email protected]]12SC(C)(C)[[email protected]@H](N1C(=O)[[email protected]]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O

Pharmacology

Indication

Used in the treatment of resistant staphylococci infections.

Structured Indications
Pharmacodynamics

Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Mechanism of action

By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor.

TargetActionsOrganism
APenicillin-binding protein 3
inhibitor
Streptococcus pneumoniae
APenicillin-binding protein 2a
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1b
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Clostridium perfringens (strain 13 / Type A)
USolute carrier family 15 member 1Not AvailableHuman
UPenicillin-binding protein 2Not AvailableStaphylococcus aureus
USolute carrier family 15 member 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

94.2 +/- 2.1% (binds to serum protein, mainly albumin)

Metabolism
Not Available
Route of elimination

Oxacillin Sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.

Half life

20 to 30 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
  • Staphylococcus aureus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolOxacillin may increase the anticoagulant activities of Acenocoumarol.Approved
AclarubicinThe serum concentration of Aclarubicin can be decreased when it is combined with Oxacillin.Investigational
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Oxacillin.Approved, Vet Approved
AmrubicinThe serum concentration of Amrubicin can be decreased when it is combined with Oxacillin.Approved, Investigational
annamycinThe serum concentration of annamycin can be decreased when it is combined with Oxacillin.Investigational
ApramycinThe serum concentration of Apramycin can be decreased when it is combined with Oxacillin.Experimental, Vet Approved
ArbekacinThe serum concentration of Arbekacin can be decreased when it is combined with Oxacillin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Oxacillin.Investigational
BekanamycinThe serum concentration of Bekanamycin can be decreased when it is combined with Oxacillin.Experimental
ChlortetracyclineThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Chlortetracycline.Approved, Investigational, Vet Approved
ClorindioneOxacillin may increase the anticoagulant activities of Clorindione.Experimental
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Oxacillin.Approved
DemeclocyclineThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Demeclocycline.Approved
DibekacinThe serum concentration of Dibekacin can be decreased when it is combined with Oxacillin.Experimental
DicoumarolOxacillin may increase the anticoagulant activities of Dicoumarol.Approved
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be decreased when it is combined with Oxacillin.Investigational, Vet Approved
DiphenadioneOxacillin may increase the anticoagulant activities of Diphenadione.Experimental
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Oxacillin.Approved, Investigational
DoxycyclineThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
EpirubicinThe serum concentration of Epirubicin can be decreased when it is combined with Oxacillin.Approved
Ethyl biscoumacetateOxacillin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindioneOxacillin may increase the anticoagulant activities of Fluindione.Investigational
FramycetinThe serum concentration of Framycetin can be decreased when it is combined with Oxacillin.Approved
GeneticinThe serum concentration of Geneticin can be decreased when it is combined with Oxacillin.Experimental
GentamicinThe serum concentration of Gentamicin can be decreased when it is combined with Oxacillin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be decreased when it is combined with Oxacillin.Experimental
GPX-150The serum concentration of GPX-150 can be decreased when it is combined with Oxacillin.Investigational
Hygromycin BThe serum concentration of Hygromycin B can be decreased when it is combined with Oxacillin.Vet Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Oxacillin.Approved
INNO-206The serum concentration of INNO-206 can be decreased when it is combined with Oxacillin.Investigational
IsepamicinThe serum concentration of Isepamicin can be decreased when it is combined with Oxacillin.Experimental
KanamycinThe serum concentration of Kanamycin can be decreased when it is combined with Oxacillin.Approved, Investigational, Vet Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxacillin.Approved
MetrizamideThe serum concentration of Metrizamide can be decreased when it is combined with Oxacillin.Approved
MicronomicinThe serum concentration of Micronomicin can be decreased when it is combined with Oxacillin.Experimental
MinocyclineThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline.Approved, Investigational
Mycophenolic acidThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.Approved
NeamineThe serum concentration of Neamine can be decreased when it is combined with Oxacillin.Experimental
NeomycinThe serum concentration of Neomycin can be decreased when it is combined with Oxacillin.Approved, Vet Approved
NetilmicinThe serum concentration of Netilmicin can be decreased when it is combined with Oxacillin.Approved, Investigational
ParomomycinThe serum concentration of Paromomycin can be decreased when it is combined with Oxacillin.Approved, Investigational
PhenindioneOxacillin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonOxacillin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Oxacillin.Approved
PirarubicinThe serum concentration of Pirarubicin can be decreased when it is combined with Oxacillin.Investigational
PlazomicinThe serum concentration of Plazomicin can be decreased when it is combined with Oxacillin.Investigational
PlicamycinThe serum concentration of Plicamycin can be decreased when it is combined with Oxacillin.Approved, Investigational, Withdrawn
ProbenecidThe serum concentration of Oxacillin can be increased when it is combined with Probenecid.Approved
PuromycinThe serum concentration of Puromycin can be decreased when it is combined with Oxacillin.Experimental
RibostamycinThe serum concentration of Ribostamycin can be decreased when it is combined with Oxacillin.Approved, Investigational
SabarubicinThe serum concentration of Sabarubicin can be decreased when it is combined with Oxacillin.Investigational
SisomicinThe serum concentration of Sisomicin can be decreased when it is combined with Oxacillin.Investigational
SP1049CThe serum concentration of SP1049C can be decreased when it is combined with Oxacillin.Investigational
SpectinomycinThe serum concentration of Spectinomycin can be decreased when it is combined with Oxacillin.Approved, Investigational, Vet Approved
StreptomycinThe serum concentration of Streptomycin can be decreased when it is combined with Oxacillin.Approved, Vet Approved
StreptozocinThe serum concentration of Streptozocin can be decreased when it is combined with Oxacillin.Approved
TioclomarolOxacillin may increase the anticoagulant activities of Tioclomarol.Experimental
TobramycinThe serum concentration of Tobramycin can be decreased when it is combined with Oxacillin.Approved, Investigational
ValrubicinThe serum concentration of Valrubicin can be decreased when it is combined with Oxacillin.Approved
WarfarinOxacillin may increase the anticoagulant activities of Warfarin.Approved
Zoptarelin doxorubicinThe serum concentration of Zoptarelin doxorubicin can be decreased when it is combined with Oxacillin.Investigational
ZorubicinThe serum concentration of Zorubicin can be decreased when it is combined with Oxacillin.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14851
KEGG Compound
C07334
PubChem Compound
6196
PubChem Substance
46505710
ChemSpider
5961
BindingDB
50350483
ChEBI
7809
ChEMBL
CHEMBL819
Therapeutic Targets Database
DAP000440
PharmGKB
PA450725
HET
105
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxacillin
ATC Codes
J01CR50 — Combinations of penicillinsJ01CF04 — Oxacillin
MSDS
Download (38 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
2CompletedTreatmentBacteremia1
2CompletedTreatmentOsteomyelitis1
2RecruitingTreatmentRectal Carcinoma1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
3CompletedTreatmentBacteremia / Bacterial Infections / Infections, Gram-Positive Bacterial1
3CompletedTreatmentInfection NOS1
3RecruitingTreatmentBacteremia1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
4CompletedTreatmentSkin Diseases, Infectious1
4TerminatedTreatmentImpaired Renal Function / S. Aureus Bacteremia / Skin and Subcutaneous Tissue Bacterial Infections1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Apothecon inc div bristol myers squibb
  • Teva pharmaceuticals usa inc
  • Baxter healthcare corp
  • Apothecon sub bristol myers squibb co
  • Elkins sinn div ah robins co inc
  • Istituto biochimico italiano spa
  • Marsam pharmaceuticals llc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous1 g/g
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous2 g/2g
Injection, powder, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/100mL
Injection, powder, for solutionIntravenous2 g/1
Injection, solutionIntravenous1 g/50mL
Injection, solutionIntravenous2 g/50mL
Powder, for solutionIntramuscular; Intravenous1 g/1
Powder, for solutionIntramuscular; Intravenous2 g/1
Powder, for solutionIntravenous10 g/100mL
Prices
Unit descriptionCostUnit
Oxacillin 10 gm vial118.01USD each
Oxacillin 2 gm vial24.08USD each
Oxacillin 1 gm vial12.41USD each
Oxacillin 2 gm/ 50 ml inj0.62USD ml
Oxacillin 1 gm/ 50 ml inj0.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)188 °CPhysProp
water solubility13.9 mg/LNot Available
logP2.38HANSCH,C ET AL. (1995)
pKa2.72SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0862 mg/mLALOGPS
logP2.05ALOGPS
logP1.7ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.75ChemAxon
pKa (Strongest Basic)-0.12ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity101.83 m3·mol-1ChemAxon
Polarizability39.61 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8002
Blood Brain Barrier-0.9923
Caco-2 permeable+0.7059
P-glycoprotein substrateNon-substrate0.6161
P-glycoprotein inhibitor INon-inhibitor0.867
P-glycoprotein inhibitor IINon-inhibitor0.922
Renal organic cation transporterNon-inhibitor0.9669
CYP450 2C9 substrateNon-substrate0.8181
CYP450 2D6 substrateNon-substrate0.8807
CYP450 3A4 substrateSubstrate0.5347
CYP450 1A2 substrateInhibitor0.5746
CYP450 2C9 inhibitorNon-inhibitor0.8725
CYP450 2D6 inhibitorNon-inhibitor0.9111
CYP450 2C19 inhibitorNon-inhibitor0.8665
CYP450 3A4 inhibitorNon-inhibitor0.665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9564
Ames testNon AMES toxic0.7304
CarcinogenicityNon-carcinogens0.5273
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity1.6583 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9997
hERG inhibition (predictor II)Non-inhibitor0.8773
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0090000000-79c009ac45201875c809
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1290000000-4d46550a2c9c9f77458a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-8890000000-4a47690fda1171ea9191
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9530000000-81bb9ec609f6a7e8c6dd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9410000000-b5c01a94c4b433924722
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9200000000-4bfc7a848a77bc668c0a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01b9-9000000000-927fa2d2be3c33adb44c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-3661f69f0fee17d6a499
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-f568ba02b1720f9fd951
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-0980000000-62551643a67b5e9a21f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-0920000000-69978fc6eeaa10c71f81
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0900000000-92b22bc2f96b5f612718
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1900000000-4dceea173f6174da433d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-3900000000-3ee73f5cb610870dbdb1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ikj-9800000000-fbc9b294222787b35a80
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0k92-9200000000-a405a812cf5f1a2f17e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9100000000-451b59b916ee627de317
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-9000000000-21eb1aa369a09320f715

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Penicillins / N-acyl-alpha amino acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Thiazolidines / Heteroaromatic compounds / Isoxazoles / Secondary carboxylic acid amides / Azetidines / Thiohemiaminal derivatives
show 10 more
Substituents
Alpha-dipeptide / Penicillin / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / Penam / Benzenoid / Monocyclic benzene moiety / Isoxazole / Tertiary carboxylic acid amide / Azole
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
penicillin (CHEBI:7809)

Targets

Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not Available
Gene Name
pbp3
Uniprot ID
Q75Y35
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp2a
Uniprot ID
Q8DNB6
Uniprot Name
Penicillin-binding protein 2a
Molecular Weight
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Cell wall formation.
Gene Name
pbpA
Uniprot ID
Q8DR59
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp1b
Uniprot ID
Q7CRA4
Uniprot Name
Penicillin-binding protein 1b
Molecular Weight
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring glycosyl groups
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
pbpA
Uniprot ID
Q8XJ01
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
75176.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Staphylococcus aureus
Pharmacological action
Unknown
General Function
Penicillin binding
Specific Function
Not Available
Gene Name
mecA
Uniprot ID
D6R448
Uniprot Name
Penicillin-binding protein 2
Molecular Weight
10694.04 Da
References
  1. Chung M, Antignac A, Kim C, Tomasz A: Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother. 2008 Aug;52(8):2709-17. doi: 10.1128/AAC.00266-08. Epub 2008 May 27. [PubMed:18505853]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G: Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51. doi: 10.1016/j.bmc.2011.06.027. Epub 2011 Jun 16. [PubMed:21741846]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 14:12